{"id":352285,"date":"2025-08-26T07:29:48","date_gmt":"2025-08-26T07:29:48","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-arcellx\/"},"modified":"2025-08-26T07:29:48","modified_gmt":"2025-08-26T07:29:48","slug":"how-to-buy-arcellx","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/","title":{"rendered":"Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arcellx, Inc. (ACLX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-352285","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcellx, Inc. (ACLX) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcellx, Inc. (ACLX) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Arcellx, Inc. (ACLX) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Arcellx, Inc. (ACLX) hisselerinin nas\u0131l al\u0131naca\u011f\u0131n\u0131 ve bu umut vadeden biyoteknoloji hissesine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin. G\u00fcncel fiyat, riskler ve 2025-2030 b\u00fcy\u00fcme potansiyelini ke\u015ffedin."},"intro":"Kanser tedavisinin gelece\u011fine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Arcellx, Inc. (ACLX) bug\u00fcn biyoteknolojideki en heyecan verici f\u0131rsatlardan birini temsil ediyor. Klinik a\u015famadaki bu \u015firket, multipl miyelom ve di\u011fer kanserlerin tedavisinde devrim yaratabilecek \u00e7\u0131\u011f\u0131r a\u00e7an sonu\u00e7larla h\u00fccre tedavisini d\u00f6n\u00fc\u015ft\u00fcr\u00fcyor. Bu hissenin neden dikkatinizi hak etti\u011fini ve yolculuklar\u0131n\u0131n bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Kanser tedavisinin gelece\u011fine yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Arcellx, Inc. (ACLX) bug\u00fcn biyoteknolojideki en heyecan verici f\u0131rsatlardan birini temsil ediyor. Klinik a\u015famadaki bu \u015firket, multipl miyelom ve di\u011fer kanserlerin tedavisinde devrim yaratabilecek \u00e7\u0131\u011f\u0131r a\u00e7an sonu\u00e7larla h\u00fccre tedavisini d\u00f6n\u00fc\u015ft\u00fcr\u00fcyor. Bu hissenin neden dikkatinizi hak etti\u011fini ve yolculuklar\u0131n\u0131n bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Performans\u0131 ve Kritik Tarihler<\/h2> <p>26 A\u011fustos 2025 itibar\u0131yla Arcellx (ACLX) hisseleri <strong>68,49 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor - bu, yat\u0131r\u0131mc\u0131lar i\u00e7in hem f\u0131rsat hem de dikkat gerektiren kritik bir seviye.<\/p> <p><strong>Takviminize not edin: 6 Kas\u0131m 2025<\/strong> bir sonraki b\u00fcy\u00fck kataliz\u00f6r. Arcellx'in 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih bu. Tarihsel olarak, bu raporlar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur:<\/p> <table> <thead> <tr><th>Tarih<\/th><th>Olay<\/th><th>Haber \u00d6ncesi Fiyat<\/th><th>Haber Sonras\u0131 De\u011fi\u015fim<\/th><\/tr> <\/thead> <tbody> <tr><td>7 A\u011fu 2025<\/td><td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>~70 $<\/td><td>%8,74 EPS s\u00fcrprizi<\/td><\/tr> <tr><td>8 May 2025<\/td><td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>~65 $<\/td><td>-%52,70 EPS ka\u00e7\u0131rma<\/td><\/tr> <tr><td>27 \u015eub 2025<\/td><td>4. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>~75 $<\/td><td>-%81,25 EPS ka\u00e7\u0131rma<\/td><\/tr> <tr><td>6 Kas 2024<\/td><td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td><td>~100 $<\/td><td>-%2,13 hafif ka\u00e7\u0131rma<\/td><\/tr> <\/tbody> <\/table> <p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Hisse senedi kazan\u00e7 sonu\u00e7lar\u0131na kar\u015f\u0131 a\u015f\u0131r\u0131 duyarl\u0131l\u0131k g\u00f6steriyor. Pozitif s\u00fcrprizler an\u0131nda s\u0131\u00e7ramalar yarat\u0131rken (%8,74 2. \u00e7eyrekte), ka\u00e7\u0131rmalar \u00f6nemli d\u00fc\u015f\u00fc\u015flere neden oluyor. Bu model, negatif kazan\u00e7 tepkilerinden sonra al\u0131m f\u0131rsatlar\u0131n\u0131n s\u0131kl\u0131kla ortaya \u00e7\u0131kt\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>  [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2> <p>Arcellx hisseleri son alt\u0131 ayda adeta bir h\u0131z treni ya\u015fad\u0131:<\/p> <p><strong>\u015eubat 2025<\/strong>: ~62,76 $ - Zorlu y\u0131l ba\u015flang\u0131c\u0131n\u0131n ard\u0131ndan hisse dip seviyelerde<br\/> <strong>Mart 2025<\/strong>: Klinik veri iyimserli\u011fiyle toparlanma ba\u015flad\u0131<br\/> <strong>May\u0131s 2025<\/strong>: ~65 $ - 1. \u00e7eyrek kazan\u00e7 ka\u00e7\u0131rmas\u0131 ge\u00e7ici gerileme yaratt\u0131<br\/> <strong>Temmuz 2025<\/strong>: ~70,95 $ - G\u00fc\u00e7l\u00fc Faz 2 verileri yenilenen g\u00fcveni tetikledi<br\/> <strong>A\u011fustos 2025<\/strong>: 68,49 $ - 2. \u00e7eyrek kazan\u00e7 s\u00fcrprizinden sonra konsolidasyon<\/p> <p>Hisse bu d\u00f6nemde <strong>%13,57<\/strong> de\u011fer kazand\u0131, \u00f6nemli volatiliteye ra\u011fmen. Yolculuk, 2025 y\u0131l\u0131n\u0131n en d\u00fc\u015f\u00fck seviyesi olan 47,86 $'dan dramatik bir toparlanmay\u0131 i\u00e7eriyor ve bu da <strong>%43'l\u00fck bir s\u0131\u00e7rama<\/strong> anlam\u0131na geliyor.<\/p>  <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Analist konsens\u00fcs\u00fc ve klinik ilerlemeye dayanarak, beklenenler \u015funlar:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: Ortalama hedef 88,72 $ (aral\u0131k 64,57 $-112,87 $) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br\/> Yakla\u015fan klinik veri yay\u0131nlar\u0131 ve potansiyel d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 yukar\u0131 y\u00f6nl\u00fc ivmeyi destekliyor.<\/li> <li><strong>2026 Tahmini<\/strong>: 84,55 $-114,75 $ \u2192 Ticarile\u015fme planlar\u0131 ilerledik\u00e7e b\u00fcy\u00fcme devam edecek<br\/> Analistler \"G\u00fc\u00e7l\u00fc Al\" derecelendirmelerini koruyor; ortalama hedef 114,75 $ %67 y\u00fckseli\u015f potansiyeli sunuyor.<\/li> <li><strong>2028 Projeksiyonu<\/strong>: Uygulama a\u015famas\u0131 - potansiyel ilk ticari lansmanlar<br\/> 538 milyon $ nakit pozisyonu, tam geli\u015ftirme i\u00e7in 2028'e kadar finansman sa\u011fl\u0131yor.<\/li> <li><strong>2030 Vizyonu<\/strong>: 167,27 $-232,72 $ \u2192 D\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc b\u00fcy\u00fcme potansiyeli<br\/> Ba\u015far\u0131l\u0131 ticarile\u015fme, mevcut seviyelerden \u00e7ok katl\u0131 getiri sa\u011flayabilir.<\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: Uzun vadeli b\u00fcy\u00fcme i\u00e7in AL, ancak yol boyunca volatiliteye haz\u0131rl\u0131kl\u0131 olun.<\/p>  <h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: \u00dcmit vaat eden verilere ra\u011fmen deneysel ila\u00e7lar\u0131n %90'\u0131 ba\u015far\u0131s\u0131z oluyor (<a href=\"https:\/\/www.biospace.com\/article\/90-percent-of-drugs-fail-clinical-trials-heres-why-\/\">Biospace<\/a>)<\/li> <li><strong>FDA onay gecikmeleri<\/strong>: D\u00fczenleyici engeller zaman \u00e7izelgesini uzatabilir<\/li> <li><strong>Mali kay\u0131plar<\/strong>: Gelir %72,4 d\u00fc\u015ferken 2. \u00e7eyrekte 52,77 milyon $ zarar<\/li> <li><strong>Sekt\u00f6r volatilitesi<\/strong>: 2025'te biyoteknoloji finansman\u0131 %57 azalarak zorluk yarat\u0131yor<\/li> <li><strong>Rekabet<\/strong>: Multipl miyelom alan\u0131nda Johnson & Johnson gibi k\u00f6kl\u00fc oyuncular<\/li> <\/ul> <h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>%97 yan\u0131t oran\u0131<\/strong>: Faz 2 denemelerinde e\u015fi benzeri g\u00f6r\u00fclmemi\u015f etkinlik<\/li> <li><strong>538 milyon $ nakit rezervi<\/strong>: Seyrelme endi\u015fesi olmadan 2028'e kadar operasyonlar\u0131 finanse ediyor<\/li> <li><strong>FDA onay\u0131<\/strong>: ACLX-004 i\u00e7in yak\u0131n zamanda al\u0131nan IND onay\u0131 d\u00fczenleyici ilerlemeyi g\u00f6steriyor<\/li> <li><strong>Kite\/Gilead ile ortakl\u0131k<\/strong>: B\u00fcy\u00fck ila\u00e7 \u015firketi onay\u0131 ve ticari uzmanl\u0131k<\/li> <li><strong>2026 lansman\u0131 planlan\u0131yor<\/strong>: Ba\u015flang\u0131\u00e7ta 160'tan fazla tedavi merkezi hedefleniyor<\/li> <\/ul>  <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %5'inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li> <li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong> - T\u00fcm\u00fcn\u00fc bir kerede de\u011fil, par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li> <li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> - 60-65 $ aral\u0131\u011f\u0131 daha iyi giri\u015f noktalar\u0131 sunabilir<\/li> <li><strong>Kas\u0131m kazan\u00e7lar\u0131n\u0131 takip edin<\/strong> - Piyasa a\u015f\u0131r\u0131 tepki verirse al\u0131m f\u0131rsat\u0131 olabilir<\/li> <li><strong>Esprili ger\u00e7eklik kontrol\u00fc<\/strong>: \"ACLX ticareti yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir - inan\u0131lmaz heyecan verici ama deneyler planland\u0131\u011f\u0131 gibi gitmedi\u011finde beklenmedik duygusal patlamalara e\u011filimlidir!\"<\/li> <\/ol>  <h2>\u2705 Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ listeleri ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td><\/tr> <tr><td>2<\/td><td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>\"ACLX\" aramas\u0131 yap\u0131n<\/td><td>Do\u011fru sonu\u00e7lar i\u00e7in sembol\u00fc kullan\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td><td>Limit emirleri volatilite s\u0131ras\u0131nda a\u015f\u0131r\u0131 \u00f6deme yapmay\u0131 \u00f6nler<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve onaylay\u0131n<\/td><td>Komisyon \u00fccretleri ve toplam maliyeti kontrol edin<\/td><\/tr> <tr><td>6<\/td><td>Pozisyonu izleyin<\/td><td>Risk y\u00f6netimi i\u00e7in %20-25 stop-loss belirleyin<\/td><\/tr> <tr><td>7<\/td><td>\u00c7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td><td>K\u00e2r alma ve zarar durdurma seviyelerini belirleyin<\/td><\/tr> <\/tbody> <\/table>  <h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2> <p>Daha b\u00fcy\u00fck miktarlarla taahh\u00fctte bulunmadan \u00f6nce stratejileri test etmek isteyenler i\u00e7in Pocket Option benzersiz avantajlar sunar:<\/p> <ul> <li><strong>Minimum depozito: 5 $<\/strong> - Ger\u00e7ek para ile pratik yapmak i\u00e7in m\u00fckemmel, \u00f6nemli risk olmadan<\/li> <li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> - Basit belge y\u00fcklemesiyle dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li> <li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> - Karlar\u0131n\u0131za \u00e7e\u015fitli y\u00f6ntemlerle eri\u015fim esnekli\u011fi<\/li> <li><strong>E\u011fitim kaynaklar\u0131<\/strong> - <a href=\"\/blog\">Pocket Option blogu<\/a> ile ticaret yaparken \u00f6\u011frenin<\/li> <\/ul>  <h2>\ud83c\udf0d 2025'te Arcellx: Kanser Tedavisinde Devrim<\/h2> <p>Arcellx, kontrol edilebilir h\u00fccre terapisi inovasyonunun \u00f6nc\u00fcs\u00fcd\u00fcr. ARC-SparX platformlar\u0131, kanser tedavisine yakla\u015f\u0131m\u0131m\u0131zda paradigma de\u011fi\u015fikli\u011fi temsil ediyor ve geleneksel CAR-T terapilerine g\u00f6re potansiyel olarak daha g\u00fcvenli ve etkili alternatifler sunuyor.<\/p> <p>\u015eirketin \u00f6nc\u00fc aday\u0131 anito-cel, di\u011fer se\u00e7enekleri t\u00fckenmi\u015f multipl miyelom hastalar\u0131nda %97 yan\u0131t oran\u0131 ile e\u015fi benzeri g\u00f6r\u00fclmemi\u015f sonu\u00e7lar g\u00f6sterdi. 2026 ticari lansman planlar\u0131 ve sekt\u00f6r devi Kite (Gilead \u015firketi) ile ortakl\u0131\u011f\u0131 sayesinde Arcellx, klinik a\u015fama geli\u015ftiricisinden ticari i\u015fletmeye d\u00f6n\u00fc\u015fmeye haz\u0131rlan\u0131yor.<\/p> <p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: 2025 y\u0131l\u0131nda Arcellx ara\u015ft\u0131rma ekibi, D-Domain teknolojilerinin sadece kanser tedavisi i\u00e7in de\u011fil, ayn\u0131 zamanda otoimm\u00fcn hastal\u0131klar i\u00e7in de umut vaat etti\u011fini ke\u015ffetti - bu da adreslenebilir pazarlar\u0131n\u0131 bir gecede ikiye katlayabilir!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Performans\u0131 ve Kritik Tarihler<\/h2>\n<p>26 A\u011fustos 2025 itibar\u0131yla Arcellx (ACLX) hisseleri <strong>68,49 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor &#8211; bu, yat\u0131r\u0131mc\u0131lar i\u00e7in hem f\u0131rsat hem de dikkat gerektiren kritik bir seviye.<\/p>\n<p><strong>Takviminize not edin: 6 Kas\u0131m 2025<\/strong> bir sonraki b\u00fcy\u00fck kataliz\u00f6r. Arcellx&#8217;in 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih bu. Tarihsel olarak, bu raporlar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur:<\/p>\n<table>\n<thead>\n<tr>\n<th>Tarih<\/th>\n<th>Olay<\/th>\n<th>Haber \u00d6ncesi Fiyat<\/th>\n<th>Haber Sonras\u0131 De\u011fi\u015fim<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>7 A\u011fu 2025<\/td>\n<td>2. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>~70 $<\/td>\n<td>%8,74 EPS s\u00fcrprizi<\/td>\n<\/tr>\n<tr>\n<td>8 May 2025<\/td>\n<td>1. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>~65 $<\/td>\n<td>-%52,70 EPS ka\u00e7\u0131rma<\/td>\n<\/tr>\n<tr>\n<td>27 \u015eub 2025<\/td>\n<td>4. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>~75 $<\/td>\n<td>-%81,25 EPS ka\u00e7\u0131rma<\/td>\n<\/tr>\n<tr>\n<td>6 Kas 2024<\/td>\n<td>3. \u00c7eyrek Kazan\u00e7lar\u0131<\/td>\n<td>~100 $<\/td>\n<td>-%2,13 hafif ka\u00e7\u0131rma<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><strong>Trend \u0130\u00e7g\u00f6r\u00fcs\u00fc<\/strong>: Hisse senedi kazan\u00e7 sonu\u00e7lar\u0131na kar\u015f\u0131 a\u015f\u0131r\u0131 duyarl\u0131l\u0131k g\u00f6steriyor. Pozitif s\u00fcrprizler an\u0131nda s\u0131\u00e7ramalar yarat\u0131rken (%8,74 2. \u00e7eyrekte), ka\u00e7\u0131rmalar \u00f6nemli d\u00fc\u015f\u00fc\u015flere neden oluyor. Bu model, negatif kazan\u00e7 tepkilerinden sonra al\u0131m f\u0131rsatlar\u0131n\u0131n s\u0131kl\u0131kla ortaya \u00e7\u0131kt\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu (\u015eubat-A\u011fustos 2025)<\/h2>\n<p>Arcellx hisseleri son alt\u0131 ayda adeta bir h\u0131z treni ya\u015fad\u0131:<\/p>\n<p><strong>\u015eubat 2025<\/strong>: ~62,76 $ &#8211; Zorlu y\u0131l ba\u015flang\u0131c\u0131n\u0131n ard\u0131ndan hisse dip seviyelerde<br \/> <strong>Mart 2025<\/strong>: Klinik veri iyimserli\u011fiyle toparlanma ba\u015flad\u0131<br \/> <strong>May\u0131s 2025<\/strong>: ~65 $ &#8211; 1. \u00e7eyrek kazan\u00e7 ka\u00e7\u0131rmas\u0131 ge\u00e7ici gerileme yaratt\u0131<br \/> <strong>Temmuz 2025<\/strong>: ~70,95 $ &#8211; G\u00fc\u00e7l\u00fc Faz 2 verileri yenilenen g\u00fcveni tetikledi<br \/> <strong>A\u011fustos 2025<\/strong>: 68,49 $ &#8211; 2. \u00e7eyrek kazan\u00e7 s\u00fcrprizinden sonra konsolidasyon<\/p>\n<p>Hisse bu d\u00f6nemde <strong>%13,57<\/strong> de\u011fer kazand\u0131, \u00f6nemli volatiliteye ra\u011fmen. Yolculuk, 2025 y\u0131l\u0131n\u0131n en d\u00fc\u015f\u00fck seviyesi olan 47,86 $&#8217;dan dramatik bir toparlanmay\u0131 i\u00e7eriyor ve bu da <strong>%43&#8217;l\u00fck bir s\u0131\u00e7rama<\/strong> anlam\u0131na geliyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Analist konsens\u00fcs\u00fc ve klinik ilerlemeye dayanarak, beklenenler \u015funlar:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: Ortalama hedef 88,72 $ (aral\u0131k 64,57 $-112,87 $) \u2192 <strong>G\u00dc\u00c7L\u00dc AL<\/strong><br \/> Yakla\u015fan klinik veri yay\u0131nlar\u0131 ve potansiyel d\u00fczenleyici d\u00f6n\u00fcm noktalar\u0131 yukar\u0131 y\u00f6nl\u00fc ivmeyi destekliyor.<\/li>\n<li><strong>2026 Tahmini<\/strong>: 84,55 $-114,75 $ \u2192 Ticarile\u015fme planlar\u0131 ilerledik\u00e7e b\u00fcy\u00fcme devam edecek<br \/> Analistler &#8220;G\u00fc\u00e7l\u00fc Al&#8221; derecelendirmelerini koruyor; ortalama hedef 114,75 $ %67 y\u00fckseli\u015f potansiyeli sunuyor.<\/li>\n<li><strong>2028 Projeksiyonu<\/strong>: Uygulama a\u015famas\u0131 &#8211; potansiyel ilk ticari lansmanlar<br \/> 538 milyon $ nakit pozisyonu, tam geli\u015ftirme i\u00e7in 2028&#8217;e kadar finansman sa\u011fl\u0131yor.<\/li>\n<li><strong>2030 Vizyonu<\/strong>: 167,27 $-232,72 $ \u2192 D\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc b\u00fcy\u00fcme potansiyeli<br \/> Ba\u015far\u0131l\u0131 ticarile\u015fme, mevcut seviyelerden \u00e7ok katl\u0131 getiri sa\u011flayabilir.<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: Uzun vadeli b\u00fcy\u00fcme i\u00e7in AL, ancak yol boyunca volatiliteye haz\u0131rl\u0131kl\u0131 olun.<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Pozitif Sinyaller<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131<\/strong>: \u00dcmit vaat eden verilere ra\u011fmen deneysel ila\u00e7lar\u0131n %90&#8217;\u0131 ba\u015far\u0131s\u0131z oluyor (<a href=\"https:\/\/www.biospace.com\/article\/90-percent-of-drugs-fail-clinical-trials-heres-why-\/\">Biospace<\/a>)<\/li>\n<li><strong>FDA onay gecikmeleri<\/strong>: D\u00fczenleyici engeller zaman \u00e7izelgesini uzatabilir<\/li>\n<li><strong>Mali kay\u0131plar<\/strong>: Gelir %72,4 d\u00fc\u015ferken 2. \u00e7eyrekte 52,77 milyon $ zarar<\/li>\n<li><strong>Sekt\u00f6r volatilitesi<\/strong>: 2025&#8217;te biyoteknoloji finansman\u0131 %57 azalarak zorluk yarat\u0131yor<\/li>\n<li><strong>Rekabet<\/strong>: Multipl miyelom alan\u0131nda Johnson &#038; Johnson gibi k\u00f6kl\u00fc oyuncular<\/li>\n<\/ul>\n<h3>2025 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>%97 yan\u0131t oran\u0131<\/strong>: Faz 2 denemelerinde e\u015fi benzeri g\u00f6r\u00fclmemi\u015f etkinlik<\/li>\n<li><strong>538 milyon $ nakit rezervi<\/strong>: Seyrelme endi\u015fesi olmadan 2028&#8217;e kadar operasyonlar\u0131 finanse ediyor<\/li>\n<li><strong>FDA onay\u0131<\/strong>: ACLX-004 i\u00e7in yak\u0131n zamanda al\u0131nan IND onay\u0131 d\u00fczenleyici ilerlemeyi g\u00f6steriyor<\/li>\n<li><strong>Kite\/Gilead ile ortakl\u0131k<\/strong>: B\u00fcy\u00fck ila\u00e7 \u015firketi onay\u0131 ve ticari uzmanl\u0131k<\/li>\n<li><strong>2026 lansman\u0131 planlan\u0131yor<\/strong>: Ba\u015flang\u0131\u00e7ta 160&#8217;tan fazla tedavi merkezi hedefleniyor<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %5&#8217;inden fazlas\u0131n\u0131 y\u00fcksek riskli biyoteknolojiye ay\u0131rmay\u0131n<\/li>\n<li><strong>Dolar maliyeti ortalamas\u0131 yap\u0131n<\/strong> &#8211; T\u00fcm\u00fcn\u00fc bir kerede de\u011fil, par\u00e7a par\u00e7a sat\u0131n al\u0131n<\/li>\n<li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> &#8211; 60-65 $ aral\u0131\u011f\u0131 daha iyi giri\u015f noktalar\u0131 sunabilir<\/li>\n<li><strong>Kas\u0131m kazan\u00e7lar\u0131n\u0131 takip edin<\/strong> &#8211; Piyasa a\u015f\u0131r\u0131 tepki verirse al\u0131m f\u0131rsat\u0131 olabilir<\/li>\n<li><strong>Esprili ger\u00e7eklik kontrol\u00fc<\/strong>: &#8220;ACLX ticareti yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir &#8211; inan\u0131lmaz heyecan verici ama deneyler planland\u0131\u011f\u0131 gibi gitmedi\u011finde beklenmedik duygusal patlamalara e\u011filimlidir!&#8221;<\/li>\n<\/ol>\n<h2>\u2705 Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ listeleri ve biyoteknoloji hisseleri sunmas\u0131na dikkat edin<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap fonlamas\u0131n\u0131 tamamlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>&#8220;ACLX&#8221; aramas\u0131 yap\u0131n<\/td>\n<td>Do\u011fru sonu\u00e7lar i\u00e7in sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in<\/td>\n<td>Limit emirleri volatilite s\u0131ras\u0131nda a\u015f\u0131r\u0131 \u00f6deme yapmay\u0131 \u00f6nler<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve onaylay\u0131n<\/td>\n<td>Komisyon \u00fccretleri ve toplam maliyeti kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Pozisyonu izleyin<\/td>\n<td>Risk y\u00f6netimi i\u00e7in %20-25 stop-loss belirleyin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>\u00c7\u0131k\u0131\u015f stratejisi planlay\u0131n<\/td>\n<td>K\u00e2r alma ve zarar durdurma seviyelerini belirleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Neden Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Uygun?<\/h2>\n<p>Daha b\u00fcy\u00fck miktarlarla taahh\u00fctte bulunmadan \u00f6nce stratejileri test etmek isteyenler i\u00e7in Pocket Option benzersiz avantajlar sunar:<\/p>\n<ul>\n<li><strong>Minimum depozito: 5 $<\/strong> &#8211; Ger\u00e7ek para ile pratik yapmak i\u00e7in m\u00fckemmel, \u00f6nemli risk olmadan<\/li>\n<li><strong>H\u0131zl\u0131 do\u011frulama<\/strong> &#8211; Basit belge y\u00fcklemesiyle dakikalar i\u00e7inde ticarete ba\u015flay\u0131n<\/li>\n<li><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> &#8211; Karlar\u0131n\u0131za \u00e7e\u015fitli y\u00f6ntemlerle eri\u015fim esnekli\u011fi<\/li>\n<li><strong>E\u011fitim kaynaklar\u0131<\/strong> &#8211; <a href=\"\/blog\">Pocket Option blogu<\/a> ile ticaret yaparken \u00f6\u011frenin<\/li>\n<\/ul>\n<h2>\ud83c\udf0d 2025&#8217;te Arcellx: Kanser Tedavisinde Devrim<\/h2>\n<p>Arcellx, kontrol edilebilir h\u00fccre terapisi inovasyonunun \u00f6nc\u00fcs\u00fcd\u00fcr. ARC-SparX platformlar\u0131, kanser tedavisine yakla\u015f\u0131m\u0131m\u0131zda paradigma de\u011fi\u015fikli\u011fi temsil ediyor ve geleneksel CAR-T terapilerine g\u00f6re potansiyel olarak daha g\u00fcvenli ve etkili alternatifler sunuyor.<\/p>\n<p>\u015eirketin \u00f6nc\u00fc aday\u0131 anito-cel, di\u011fer se\u00e7enekleri t\u00fckenmi\u015f multipl miyelom hastalar\u0131nda %97 yan\u0131t oran\u0131 ile e\u015fi benzeri g\u00f6r\u00fclmemi\u015f sonu\u00e7lar g\u00f6sterdi. 2026 ticari lansman planlar\u0131 ve sekt\u00f6r devi Kite (Gilead \u015firketi) ile ortakl\u0131\u011f\u0131 sayesinde Arcellx, klinik a\u015fama geli\u015ftiricisinden ticari i\u015fletmeye d\u00f6n\u00fc\u015fmeye haz\u0131rlan\u0131yor.<\/p>\n<p><strong>\u0130lgin\u00e7 Bilgi<\/strong>: 2025 y\u0131l\u0131nda Arcellx ara\u015ft\u0131rma ekibi, D-Domain teknolojilerinin sadece kanser tedavisi i\u00e7in de\u011fil, ayn\u0131 zamanda otoimm\u00fcn hastal\u0131klar i\u00e7in de umut vaat etti\u011fini ke\u015ffetti &#8211; bu da adreslenebilir pazarlar\u0131n\u0131 bir gecede ikiye katlayabilir!<\/p>\n"},"faq":[{"question":"Arcellx, Inc. (ACLX) hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"ACLX\" sembol\u00fc ile arama yap\u0131n, uygun sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in ve i\u015flemi onaylay\u0131n."},{"question":"Arcellx hisselerinin 2025-2030 fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda ortalama hedef 88,72 $, 2030'da ise 167,27 $ ile 232,72 $ aras\u0131nda de\u011fi\u015fen g\u00fc\u00e7l\u00fc b\u00fcy\u00fcme potansiyeli bulunmaktad\u0131r."},{"question":"Arcellx'in en b\u00fcy\u00fck riskleri nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, FDA onay gecikmeleri, mali kay\u0131plar, sekt\u00f6r volatilitesi ve g\u00fc\u00e7l\u00fc rekabet ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar Arcellx hisseleri al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn %5'inden fazlas\u0131n\u0131 ay\u0131rmamak, dolar maliyeti ortalamas\u0131 yapmak, fiyat uyar\u0131lar\u0131 kurmak ve \u00f6nemli kazan\u00e7 raporlar\u0131n\u0131 takip etmek \u00f6nerilir."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7oklu para \u00e7ekme se\u00e7enekleri ve kapsaml\u0131 e\u011fitim kaynaklar\u0131 sunmas\u0131 nedeniyle yeni yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Arcellx, Inc. (ACLX) hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 fonlay\u0131n, \"ACLX\" sembol\u00fc ile arama yap\u0131n, uygun sipari\u015f t\u00fcr\u00fcn\u00fc se\u00e7in ve i\u015flemi onaylay\u0131n."},{"question":"Arcellx hisselerinin 2025-2030 fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda ortalama hedef 88,72 $, 2030'da ise 167,27 $ ile 232,72 $ aras\u0131nda de\u011fi\u015fen g\u00fc\u00e7l\u00fc b\u00fcy\u00fcme potansiyeli bulunmaktad\u0131r."},{"question":"Arcellx'in en b\u00fcy\u00fck riskleri nelerdir?","answer":"Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, FDA onay gecikmeleri, mali kay\u0131plar, sekt\u00f6r volatilitesi ve g\u00fc\u00e7l\u00fc rekabet ba\u015fl\u0131ca risklerdir."},{"question":"Yeni ba\u015flayanlar Arcellx hisseleri al\u0131rken nelere dikkat etmeli?","answer":"Portf\u00f6y\u00fcn %5'inden fazlas\u0131n\u0131 ay\u0131rmamak, dolar maliyeti ortalamas\u0131 yapmak, fiyat uyar\u0131lar\u0131 kurmak ve \u00f6nemli kazan\u00e7 raporlar\u0131n\u0131 takip etmek \u00f6nerilir."},{"question":"Pocket Option neden yeni yat\u0131r\u0131mc\u0131lar i\u00e7in uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama, \u00e7oklu para \u00e7ekme se\u00e7enekleri ve kapsaml\u0131 e\u011fitim kaynaklar\u0131 sunmas\u0131 nedeniyle yeni yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcellx, Inc. (ACLX) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcellx, Inc. (ACLX) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T07:29:48+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arcellx, Inc. (ACLX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-26T07:29:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/\",\"name\":\"Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcellx, Inc. (ACLX) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"datePublished\":\"2025-08-26T07:29:48+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arcellx, Inc. (ACLX) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcellx, Inc. (ACLX) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/","og_locale":"tr_TR","og_type":"article","og_title":"Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcellx, Inc. (ACLX) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-26T07:29:48+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arcellx, Inc. (ACLX) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-26T07:29:48+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/","name":"Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r - Arcellx, Inc. (ACLX) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","datePublished":"2025-08-26T07:29:48+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals15-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-arcellx\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Arcellx, Inc. (ACLX) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Arcellx, Inc. (ACLX) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":352292,"slug":"how-to-buy-arcellx","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Arcellx, Inc. (ACLX) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Arcellx, Inc. (ACLX)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-arcellx\/"},"pt_AA":{"locale":"pt_AA","id":352291,"slug":"how-to-buy-arcellx","post_title":"Como comprar a\u00e7\u00f5es da Arcellx, Inc. (ACLX) - Investimento em a\u00e7\u00f5es da Arcellx, Inc. (ACLX)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-arcellx\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/352285","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=352285"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/352285\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334117"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=352285"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=352285"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=352285"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}